/
Oncology
Metastatic Pancreatic Ductal Adenocarcinoma
12
Pipeline Programs↗
8
Active Trials↗
10
Companies Involved↗
Metastatic Pancreatic Ductal Adenocarcinoma is an emerging landscape with 12 programs across 10 companies. The most active players are AbbVie.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 1
No programs
Phase 24
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
73%
Small molecule
8 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 92% of 12 pipeline programs.
Analysis
Trial Status
12
clinical trials
Recruiting5 · 42%
Active, not recruiting2 · 17%
Completed2 · 17%
Suspended1 · 8%
Not yet recruiting1 · 8%
Terminated1 · 8%
Clinical Trials
Trial Activity
12 trials
A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Recruiting·—·Phase 2·NCT06843551·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)